Study ID: ECOG E2906
Title:

Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)

Description:

This study is being done to determine which treatment is best for older patients with AML. Participants in this study are over 60 years of age and have been recently diagnosed with acute myeloid leukemia (AML). This study has three parts; the first part of this study, (induction chemotherapy) patients will be treated with one of two different chemotherapy regimens. The second part of this study; patients will receive either an allogeneic transplant or consolidation chemotherapy (after induction therapy) to prevent relapse (cancer returning). In part three of this study; patients will either be closely observed monthly for 12 months or treated with decitabine.

Location:
Bemidji Clinic, Fargo Region, Sioux Falls Region
Principal Investigator:
Miroslaw Mazurczak MD,Preston Steen, MD,Preston Steen, MD
Disease:
AML (Acute Myelogenic Leukemia)
Stage:
Phase III

Status:

Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.

Back to Clinical Trials list